Financial Contrast: eXoZymes (EXOZ) versus Its Competitors

eXoZymes (NASDAQ:EXOZ) is one of 617 public companies in the “MED – BIOMED/GENE” industry, but how does it weigh in compared to its rivals? We will compare eXoZymes to related businesses based on the strength of its institutional ownership, earnings, profitability, valuation, dividends, analyst recommendations and risk.

Insider and Institutional Ownership

51.2% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 72.4% of eXoZymes shares are owned by company insiders. Comparatively, 13.5% of shares of all “MED – BIOMED/GENE” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares eXoZymes and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
eXoZymes	$70,000.00	-$5.86 million	-14.92
eXoZymes Competitors	$893.59 million	-$44.13 million	10.08

eXoZymes’ rivals have higher revenue, but lower earnings than eXoZymes. eXoZymes is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of current ratings for eXoZymes and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1	0	0	0	1.00
eXoZymes Competitors	6636	12471	38217	1215	2.58

As a group, “MED – BIOMED/GENE” companies have a potential upside of 52.64%. Given eXoZymes’ rivals stronger consensus rating and higher possible upside, analysts plainly believe eXoZymes has less favorable growth aspects than its rivals.

Profitability

This table compares eXoZymes and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-104.58%	-79.55%
eXoZymes Competitors	-906.16%	-572.54%	-29.84%

Summary

eXoZymes rivals beat eXoZymes on 8 of the 12 factors compared.

eXoZymes Company Profile

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.